Therefore more malignant cells express CEACAM-1 in melanoma, while in other tumour entities such as breast or prostate cancer CEACAM-1 expression is down-regulated during malignant progression [39], [40]. This evidence concerns the gene CEACAM1 and prostate carcinoma.